安进地诺单抗可以治疗骨质疏松吗？

Can Amgen denosumab treat osteoporosis? Multiple trials have shown that (XGEVA) produced by the American company Amgen is highly effective in the treatment of osteoporosis in postmenopausal women.

Amgen's denosumab is the first approved monoclonal antibody that specifically targets a RANK ligand. RANK ligand is a transmembrane or soluble protein that is necessary for osteoclasts to maintain their structure, function, and survival. Human RANKL mRNA is mainly found in bones, bone marrow and lymphoid tissues. Its main function in bones is to stimulate the differentiation and activity of osteoclasts and inhibit the apoptosis of osteoclasts. The FDA approved denosumab for use in postmenopausal women with osteoporosis who are at high risk for fractures to help reduce the incidence of vertebral, non-vertebral and hip fractures in postmenopausal women with osteoporosis. This product is also used in patients for whom other current treatments are ineffective or intolerable to reduce the risk of fractures.

Data from an Amgen study: denosumab was better than zoledronic acid in preventing complications of bone metastases from solid tumors or multiple myeloma. Compared with zoledronic acid, denosumab can significantly delay the onset of SREs in patients with breast cancer bone metastases, reduce the risk of multiple SREs by 23%, significantly delay the onset of pain by 3.9 months, and reduce the use of powerful opioid analgesics. In addition, the subcutaneous injection of Xgeva (desosumab) has greatly improved patients' medication compliance. At present, many domestic and foreign authoritative guidelines have unanimously affirmed the status of denosumab in breast cancer bone metastasis, and recommended that Xgeva (desomasumab) should be started after the diagnosis of breast cancer bone metastasis.

Recommended related hot articles: /newsDetail/85814.html